Search results for "Chemoprophylaxis"

showing 10 items of 24 documents

Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin.

1993

Since 1972, a large number of studies have shown that intravesical treatment with doxorubicin (adriamycin) is effective against carcinoma in situ and multiple papillary tumors. Furthermore, it significantly reduces the recurrence rate after transurethral resection. Its efficacy has been compared with that of Bacillus Calmette-Guerin (BCG), which is the only treatment accepted by the US Food and Drug Administration for therapy of carcinoma in situ (Tis). In more recent years, a few studies have been performed using intravesical epirubicin in the hope that different properties of the molecule might enhance the activity of the anthracyclines, but produce fewer and milder side-effects. After we…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyUrologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicineHumansPharmacology (medical)DoxorubicinEpirubicinPharmacologyChemotherapyUrinary bladderbusiness.industryCarcinoma in situCancermedicine.diseaseSurgeryInfectious Diseasesmedicine.anatomical_structureAdministration IntravesicalOncologyUrinary Bladder NeoplasmsDoxorubicin030220 oncology & carcinogenesisChemoprophylaxisbusinessCarcinoma in SituEpirubicinmedicine.drugJournal of chemotherapy (Florence, Italy)
researchProduct

Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors

2003

Morbidity and mortality in patients with malignancies, especially leukemia and lymphoma, are increased by invasive fungal infections. Since diagnosis of invasive fungal infection is often delayed, antifungal prophylaxis is an attractive approach for patients expecting prolonged neutropenia. Antifungal prophylaxis has obviously attracted much interest resulting in dozens of clinical trials since the late 1970s. The non-absorbable polyenes are probably ineffective in preventing invasive fungal infections, but may reduce superficial mycoses. Intravenous amphotericin B and the newer azoles were used in clinical trials, but their role in antifungal prophylaxis is still not well defined. Allogene…

0303 health sciencesmedicine.medical_specialty030306 microbiologybusiness.industryOpportunistic infectionItraconazoleHematologyGeneral MedicineNeutropeniamedicine.disease3. Good healthClinical trial03 medical and health sciences0302 clinical medicineAmphotericin BChemoprophylaxisImmunologyMedicine030212 general & internal medicinebusinessIntensive care medicineMycosisFluconazolemedicine.drugAnnals of Hematology
researchProduct

Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma.

2003

To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences. GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations…

AdultMaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentUrologySettore MED/24 - UrologiaSuperficial bladder carcinoma GP-170 MDR-1 Prognosis Intravesical chemotherapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansATP Binding Cassette Transporter Subfamily B Member 1Stage (cooking)AgedRetrospective StudiesChemotherapyHematologyUrinary bladderbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisDrug Resistance MultipleGene Expression Regulation NeoplasticTransitional cell carcinomamedicine.anatomical_structureOncologyUrinary Bladder NeoplasmsChemotherapy AdjuvantDrug Resistance NeoplasmChemoprophylaxisFemaleSuperficial Bladder CarcinomaGenes MDRNeoplasm Recurrence LocalbusinessFollow-Up StudiesJournal of cancer research and clinical oncology
researchProduct

Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry

2009

Patients surviving invasive fungal disease (IFD) and needing further antineoplastic chemotherapy are at high risk of recurrent fungal infection. In the absence of randomised controlled trials in this area, secondary prophylactic regimens are diverse. From 448 patients registered with the Multinational Case Registry of Secondary Antifungal Prophylaxis, we performed an analysis of patients receiving caspofungin (CAS) or itraconazole (ITC). All patients had an underlying haematological malignancy and had been diagnosed with an episode of IFD earlier in their course of treatment. Data collected comprised demographics, underlying disease, first episode of IFD, antifungal prophylaxis, incidence a…

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsAdolescentItraconazoleAspergillosisChemopreventionEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundCaspofunginInternal medicinemedicineHumansAspergillosisPharmacology (medical)RegistriesMycosisAgedFirst episodebusiness.industryIncidence (epidemiology)Stem cell transplantationGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTransplantationTreatment OutcomeInfectious DiseasesMycoseschemistryHematologic NeoplasmsChemoprophylaxisFemaleAntifungal prophylaxisItraconazoleCaspofunginbusinessmedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): a matched-pair study comparing oral fl…

2005

The safety and efficacy of early bacterial prophylaxis with piperacillin-tazobactam were prospectively evaluated in 51 autologous peripheral blood stem cell transplantation (PBSCT) recipients. The results were compared with those obtained in 51 control patients receiving oral fluoroquinolones in a retrospective matched-pair control study. Overall, 76% of the study group and 98% of the control group developed at least one febrile episode during neutropenia (P=0.002). Time from neutropenia to the first febrile episode (FFE) was significantly longer in the study group than in the control group (P=0.04). Once a febrile episode appeared, the duration of fever was significantly longer in cases th…

AdultMalemedicine.medical_specialtyNeutropeniaAdolescentFevermedicine.drug_classMatched-Pair AnalysisPremedicationAntibioticsPenicillanic AcidBacteremiaGram-Positive BacteriaTazobactamTransplantation AutologousInternal medicineAmphotericin BGram-Negative Bacteriapolycyclic compoundsmedicineHumansAntibacterial agentAgedPiperacillinTransplantationPeripheral Blood Stem Cell TransplantationHematologybusiness.industryHematologyBacterial InfectionsMiddle AgedSurgeryPiperacillin Tazobactam Drug CombinationPiperacillin/tazobactamChemoprophylaxisFemaleStem cellbusinessPiperacillinmedicine.drugFluoroquinolonesBone marrow transplantation
researchProduct

The Respect of Recommendations Provided in an International Travelers' Medical Service: Far From the Cup to the Lips

2013

Equipe plutôt EA Pôle MERS CT3 EJ3; Background: It is not clearly known how frequently the recommendations given to travelers are followed, and what factors could encourage compliance with these recommended measures. Methods: Adults consulting at a Medical Department for International Travelers (International Travelers' Medical Services, ITMS) in October and November 2010 were asked to answer a questionnaire before their journey. They were also contacted for a post-travel telephone interview to determine whether they had followed the recommendations regarding vaccinations and malaria prevention, and the reasons for poor or noncompliance with these recommendations. Results A total of 353 tra…

Adultmedicine.medical_specialtyPediatricsMultivariate analysisprévention conseil[SDV]Life Sciences [q-bio]MEDLINEDirective CounselingChemopreventionAntimalarialsRisk FactorsSurveys and QuestionnairesHealth careOutcome Assessment Health CarePreventive Health ServicesMedicineTravel medicineHumans[SDV.BV]Life Sciences [q-bio]/Vegetal BiologyMedical prescriptionTravelMosquito Netsbusiness.industryVaccinationGeneral MedicineMiddle AgedMalariaTelephone interviewSocioeconomic FactorsFamily medicineChemoprophylaxis[SDE]Environmental SciencesMosquito netPatient ComplianceFemaleFrancebusinesshuman activitiesTravel Medicine
researchProduct

Immune Tolerance Induction in Hemophilia A: A Review

2003

In this article, a comparative analysis of the data stemming from the studies conducted in the field of immune tolerance treatment (ITT) of hemophilia A was attempted. Comparisons are difficult because previous studies differ in many respects, including the dosage of factor (F) VIII, the number of FVIII administrations per day, the association with immunosuppressive drugs (prednisone, cyclophosphamide), and, most importantly, the definition of success in terms of the reacquisition of tolerance. However, a number of variables consistently influenced outcome: the inhibitor titer, either the maximum one or the one assayed before immune tolerance (IT) start and age. As to the FVIII dose, result…

Adultmedicine.medical_specialtyTime FactorsAdolescentDoseCyclophosphamideHemophilia AImmune toleranceVon Willebrand factorPrednisoneInternal medicineImmune ToleranceCoagulopathyHumansMedicineChildFactor VIIIbiologybusiness.industryInfantHematologymedicine.diseaseRecombinant ProteinsKineticsTreatment OutcomeChild PreschoolImmunologyChemoprophylaxisbiology.proteinCardiology and Cardiovascular MedicinebusinessBypassing agentmedicine.drugSeminars in Thrombosis and Hemostasis
researchProduct

Low-dose budesonide treatment for prevention of postoperative recurrence of Crohnʼs disease

1999

Summary and ConclusionAlthough the effect of budesonide was altogether positive in almost all variables studied in this train (e.g. endoscopic and histopathological score, time-to-failure, CDAI, patients' global judgement and rate of side effects), this increase in efficacy was small and the power f

Budesonidemedicine.medical_specialtyCrohn's diseaseHepatologymedicine.diagnostic_testbusiness.industrymedicine.drug_classGastroenterologyPlacebo-controlled studyColonoscopymedicine.diseaseGastroenterologylaw.inventionSurgeryClinical trialRandomized controlled triallawInternal medicineChemoprophylaxismedicineCorticosteroidbusinessmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

Intravesical mitoxantrone in superficial bladder tumours (Ta-T1)

1993

Abstract 36 patients with histologically proven grade G1–G2, Ta-T1 transitional cell carcinoma of the bladder were introduced, after transurethral resection (TUR), into a study of intravesical chemoprophylaxis with mitoxantrone (20 mg diluted in 50 ml). After a mean follow-up of 23 months, 16 (50%) patients showed a superficial recurrence with a mean recurrence rate of 0.56 per year. In 19 patients with recurring tumours the mean recurrence rate decreased from 1.65 to 0.58 per year. 9 patients (25.7%) suffered from a chemical cystitis that in 2 cases (5.7%) required treatment interruption.

Cancer Researchmedicine.medical_specialtymedicine.medical_treatmentUrologyResectionCystitismedicineHumansCarcinoma Transitional CellMitoxantroneChemotherapyUrinary bladderbusiness.industrymedicine.diseaseSurgeryChemical cystitisAdministration IntravesicalTransitional cell carcinomamedicine.anatomical_structureUrinary Bladder NeoplasmsOncologyTreatment interruptionChemoprophylaxisMitoxantroneNeoplasm Recurrence Localbusinessmedicine.drugEuropean Journal of Cancer
researchProduct

LOCAL MICROWAVE HYPERTHERMIA AND INTRAVESICAL CHEMOTHERAPY AS BLADDER SPARING TREATMENT FOR SELECT MULTIFOCAL AND UNRESECTABLE SUPERFICIAL BLADDER TU…

1998

Purpose: The role of a combined regimen of local hyperthermia and topical chemotherapy in patients with multifocal and recurrent superficial bladder tumors not curable by transurethral resection was evaluated in a neodjuvant organ sparing clinical study. Materials and Methods: A total of 19 patients with multifocal, superficial grades 1 to 3 bladder tumors that recurred after intravesical chemoprophylaxis or immunoprophylaxis underwent local combined administration of microwave induced hyperthermia and intravesical chemotherapy as a debulking approach. Due to extensive superficial involvement of the bladder walls complete transurethral resection of all tumors seemed technically unfeasible i…

HyperthermiaAdultMalemedicine.medical_specialtymedicine.medical_treatmentUrologyAntineoplastic AgentsCystectomyBladder NeoplasmmedicineHumansMicrowavesAgedAged 80 and overChemotherapyCarcinoma Transitional CellUrinary bladderbusiness.industryintravesical chemotherapy bladder cancer microwave hyperthermiaHyperthermia InducedMiddle Agedmedicine.diseaseDebulkingSurgeryRegimenmedicine.anatomical_structureAdministration IntravesicalUrinary Bladder NeoplasmsChemoprophylaxisFeasibility StudiesFemaleNeoplasm Recurrence LocalbusinessThe Journal of Urology
researchProduct